Estrogen Hormone Protocol
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00000177 |
|
Recruitment Status :
Completed
First Posted : November 1, 1999
Last Update Posted : December 11, 2009
|
Sponsor:
National Institute on Aging (NIA)
Information provided by:
National Institute on Aging (NIA)
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
Estrogen is a hormone that is dominant in the female reproductive system. In women, most estrogen is produced by the ovaries. Men produce estrogen by converting testosterone into estrogen. Because this hormone also has many beneficial effects on brain cells, it currently is being studied as a treatment for Alzheimer's disease. The enzyme that forms the neurotransmitter acetylcholine is promoted in the presence of estrogen. Several very small clinical studies have demonstrated improvement in cognitive function and mood measures in women with Alzheimer's disease who take estrogen.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Alzheimer Disease | Drug: Estrogen | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Enrollment : | 120 participants |
| Allocation: | Randomized |
| Masking: | Double |
| Primary Purpose: | Treatment |
| Study Start Date : | October 1995 |
| Actual Primary Completion Date : | January 1999 |
| Actual Study Completion Date : | January 1999 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Alzheimer disease
Drug Information available for:
Estrogens
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 60 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Women with a diagnosis of Alzheimer's disease who currently are not taking estrogen replacement therapy, who have had a hysterectomy, and who are in stable general health.
Exclusion Criteria:
- Patients with an uncontrolled health problem, such as untreated high blood pressure or thyroid disease.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000177
Locations
Show 25 study locations
Sponsors and Collaborators
National Institute on Aging (NIA)
Investigators
| Principal Investigator: | Leon Thal, MD. | University of California, San Diego |
Additional Information:
Publications of Results:
Publications of Results:
| ClinicalTrials.gov Identifier: | NCT00000177 |
| Other Study ID Numbers: |
IA0001 3U01AG010483-08S2 ( U.S. NIH Grant/Contract ) |
| First Posted: | November 1, 1999 Key Record Dates |
| Last Update Posted: | December 11, 2009 |
| Last Verified: | September 2009 |
Keywords provided by National Institute on Aging (NIA):
|
Alzheimer's disease Estrogen |
Additional relevant MeSH terms:
|
Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases |
Neurocognitive Disorders Mental Disorders Estrogens Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs |